Spyre Therapeutics (NASDAQ:SYRE - Get Free Report)'s stock had its "outperform" rating restated by research analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They presently have a $65.00 price objective on the stock. Wedbush's price objective would suggest a potential upside of 201.62% from the company's current price.
Other equities analysts have also issued reports about the company. Guggenheim increased their price objective on Spyre Therapeutics from $50.00 to $65.00 and gave the company a "buy" rating in a research report on Friday, October 25th. Robert W. Baird increased their price objective on Spyre Therapeutics from $50.00 to $65.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $54.83.
Check Out Our Latest Report on Spyre Therapeutics
Spyre Therapeutics Stock Down 4.1 %
Shares of Spyre Therapeutics stock traded down $0.91 during trading on Monday, hitting $21.55. 715,627 shares of the stock traded hands, compared to its average volume of 581,290. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -2.88 and a beta of 2.86. The firm's fifty day moving average is $27.39 and its 200-day moving average is $28.18. Spyre Therapeutics has a 52 week low of $20.07 and a 52 week high of $47.97.
Hedge Funds Weigh In On Spyre Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Amalgamated Bank bought a new position in Spyre Therapeutics during the 2nd quarter worth approximately $28,000. Quest Partners LLC purchased a new stake in Spyre Therapeutics in the 2nd quarter worth approximately $36,000. Carlyle Group Inc. purchased a new stake in Spyre Therapeutics in the 2nd quarter worth approximately $227,000. Intech Investment Management LLC purchased a new stake in Spyre Therapeutics in the 3rd quarter worth approximately $246,000. Finally, Profund Advisors LLC purchased a new stake in Spyre Therapeutics in the 2nd quarter worth approximately $296,000. 80.39% of the stock is currently owned by institutional investors.
Spyre Therapeutics Company Profile
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
